KKR proposes plan to buy Walgreens in $70B deal

Amy Baxter | | Health Exec | Policy & Regulations
Target health care costs.

Private equity group KKR has offered a $70 billion buyout proposal to Walgreens Boots Alliance, the Financial Times reported.

Rumors of the deal were first reported last week. It would bring Walgreens from a public company to private ownership, and KKR would need other big investors to complete the deal, according to the Financial Times. In addition, shareholders and senior management at Walgreens are in talks to contribute to taking the company private in some capacity. The company’s chairman, Stefano Pessina, owns 16% of the business.

Talks of a private equity deal come at a time when Walgreens has seen a major decline in its stock price, with a drop of nearly 20% from January through October this year. The deal would be one of the biggest private takeovers ever and could prove to be difficult, particularly as Walgreens has enacted cost-cutting measures by cutting stores and laying off employees to save a targeted $1.8 billion by 2022.

KKR has been a long-time investor with Walgreens and backed the company’s 2007 buyout of Boots Alliance.

See the full story below:

KKR outlines Walgreens Boots $70bn takeover plan

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

HHS employees offered two months of pay to quit their jobs
To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
CMS ends ACA special enrollment, changes deadline for signing up
Report: NIH continues to pull research grants, in violation of court orders
HHS sends 80K workers a $25K ‘voluntary’ resignation notice
More than 1,000 hospitals earn $700M opioid crisis judgment

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.